AIM: To investigate the SLCO1B1 388A>G and 521T>C polymorphisms in hyperlipidemia patients and evaluate the effect of the two polymorphisms on the lipid-lowering efficacy of pitavastatin. METHODS: The functional polymorphisms of SLCO1B1 (388A>G and 521T>C) were genotyped in 140 Chinese patients with essential hyperlipidemia using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and one-step tetra-primers ARMS-PCR. Eighty-five patients were enrolled in the clinical trial and given 2 mg of pitavastatin daily for 8 weeks. Total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) serum levels were measured at baseline, after 4 weeks and after 8 weeks of treatment. RESULTS: The allele frequencies of SLCO1B1 388A>G and 521T>C in essential hyperlipidemia patients were 71.1% and 11.1%, respectively. The 4- and 8-week treatment with pitavastatin significantly reduced TC, TG, and LDL levels, but there was no statistical difference among patients with wild type, SLCO1B1 388A>G or SLCO1B1 521T>C in the lipid-lowering efficacy of pitavastatin. CONCLUSION: The present study found that the allele frequencies of SLCO1B1 388A>G and 521T>C in Chinese patients with essential hyperlipidemia are comparable to those in healthy Chinese population. SLCO1B1 388A>G and 521T>C do not affect the lipid-lowering efficacy of pitavastatin.
AIM: To investigate the SLCO1B1 388A>G and 521T>C polymorphisms in hyperlipidemiapatients and evaluate the effect of the two polymorphisms on the lipid-lowering efficacy of pitavastatin. METHODS: The functional polymorphisms of SLCO1B1 (388A>G and 521T>C) were genotyped in 140 Chinese patients with essential hyperlipidemia using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and one-step tetra-primers ARMS-PCR. Eighty-five patients were enrolled in the clinical trial and given 2 mg of pitavastatin daily for 8 weeks. Total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) serum levels were measured at baseline, after 4 weeks and after 8 weeks of treatment. RESULTS: The allele frequencies of SLCO1B1 388A>G and 521T>C in essential hyperlipidemiapatients were 71.1% and 11.1%, respectively. The 4- and 8-week treatment with pitavastatin significantly reduced TC, TG, and LDL levels, but there was no statistical difference among patients with wild type, SLCO1B1 388A>G or SLCO1B1 521T>C in the lipid-lowering efficacy of pitavastatin. CONCLUSION: The present study found that the allele frequencies of SLCO1B1 388A>G and 521T>C in Chinese patients with essential hyperlipidemia are comparable to those in healthy Chinese population. SLCO1B1 388A>G and 521T>C do not affect the lipid-lowering efficacy of pitavastatin.
Authors: J F Thompson; M Man; K J Johnson; L S Wood; M E Lira; D B Lloyd; P Banerjee; P M Milos; S P Myrand; J Paulauskis; M A Milad; W J Sasiela Journal: Pharmacogenomics J Date: 2005 Impact factor: 3.550
Authors: Michael Igel; Katja A Arnold; Mikko Niemi; Ute Hofmann; Matthias Schwab; Dieter Lütjohann; Klaus von Bergmann; Michel Eichelbaum; Kari T Kivistö Journal: Clin Pharmacol Ther Date: 2006-04-11 Impact factor: 6.875
Authors: I Ieiri; S Suwannakul; K Maeda; H Uchimaru; K Hashimoto; M Kimura; H Fujino; M Hirano; H Kusuhara; S Irie; S Higuchi; Y Sugiyama Journal: Clin Pharmacol Ther Date: 2007-04-25 Impact factor: 6.875
Authors: Wendy M van der Deure; Edith C H Friesema; Frank Jan de Jong; Yolanda B de Rijke; Frank H de Jong; André G Uitterlinden; Monique M B Breteler; Robin P Peeters; Theo J Visser Journal: Endocrinology Date: 2008-05-22 Impact factor: 4.736
Authors: E Link; S Parish; J Armitage; L Bowman; S Heath; F Matsuda; I Gut; M Lathrop; R Collins Journal: N Engl J Med Date: 2008-07-23 Impact factor: 91.245
Authors: Damiano Baldassarre; Mauro Amato; Beatrice Frigerio; Gualtiero Columbo; Philip F Binkley; Saurabh R Pandey; Adam M Suhy; Katherine Hartmann; Joseph P Kitzmiller Journal: G Ital Arterioscler Date: 2013-11
Authors: Joseph P Kitzmiller; Philip F Binkley; Saurabh R Pandey; Adam M Suhy; Damiano Baldassarre; Katherine Hartmann Journal: Discov Med Date: 2013-08 Impact factor: 2.970
Authors: A Daka Grapci; A J Dimovski; A Kapedanovska; M Vavlukis; A Eftimov; N Matevska Geshkovska; N Labachevski; K Jakjovski; D Gorani; S Kedev; K Mladenovska Journal: Balkan J Med Genet Date: 2015-12-30 Impact factor: 0.519